SEATTLE, Oct. 9, 2026 — Kapta Space, a developer of next-generation spaceborne radar payloads, today announced a $24 million Series A financing led by Washington Harbour Partners and co-led by Bison Ventures, with participation from MetaVC and a group of new and existing investors including MYDA Capital, Entrada Ventures, Aurelia Foundry, and Fitz Gate Ventures. The round brings Kapta’s total funding to $30 million.

The funding will help Kapta scale production of its technology to support multiple classified moving target indication (MTI) contracts the company secured earlier this year.

Kapta was founded to address a central challenge in space-based radar intelligence, surveillance, and reconnaissance (ISR): delivering the persistent coverage needed to detect and maintain custody of moving threats across air, sea, and land. Conventional radar payloads have historically been too costly and complex to deploy across the large satellite constellations these missions require.

Kapta’s modular Metamaterial Electronically Scanned Array (MESA™) architecture rethinks how electronically steerable radar payloads are built. This software-defined architecture is designed to deliver advanced radar performance with significantly lower cost, power requirements, and manufacturing complexity than traditional AESA approaches, unlocking a path to sensing at scale.

The challenge in persistent spaceborne awareness is not simply detecting and tracking a target; it’s maintaining custody as that target moves. Kapta’s electronically steerable radar architecture combines wide field-of-regard, rapid beam steering, and scalable apertures to enable spacecraft to search, track, revisit, and maintain awareness of dynamic targets at mission scale.

“The mission calls for persistent awareness, and that requires us to rethink how radar has to work at constellation scale,” said Milton Perque, Founder and CEO of Kapta Space. “Traditional architectures are cost-prohibitive and were never designed for the scale these missions now demand. This investment allows us to advance our technology, expand manufacturing, and work with strategic partners to bring that capability through flight qualification and into contracted orbital missions, opening the door to a new class of persistent tracking and advanced ISR missions from orbit.”

“For decades, traditional AESA payloads have been too costly and complex to deploy at the scale required for missions like MTI,” said Mina Faltas, Founder and CEO of Washington Harbour Partners. “Kapta’s MESA architecture changes that equation with a modular, highly manufacturable approach to electronically steerable radar. We believe its combination of performance, cost, and scalability will make Kapta a foundational supplier to the next generation of U.S. and allied space architectures, and we’re thrilled to lead the Series A.”

“Kapta is rethinking a critical system from first principles,” said Ben Hemani, Founding Partner at Bison Ventures. “By making space-based radar more scalable, cost-effective, and manufacturable, the team is enabling persistent sensing at a scale traditional architectures simply weren’t built to support. That kind of enabling technology, with the potential for massive real-world impact, is exactly what we look for at Bison.”

Following the Series A, Kapta will focus on qualifying its payload for flight, expanding manufacturing capacity, and preparing for its first orbital demonstration. These sophisticated demo missions will move the company closer to supplying radar payloads at the scale that future MTI missions demand.

About Kapta Space
Seattle-based Kapta Space develops advanced, electronically steered radar payloads for next-generation spaceborne intelligence, surveillance, reconnaissance, and tracking missions. Its technology is designed to enable moving target indication (MTI), wide-area tracking of dynamic targets, and high-resolution SAR imaging from low Earth orbit. With rapid electronic beam steering, broad field of regard, and persistent revisit capability, Kapta’s payloads are intended to support demanding national security missions that require responsive detection, tracking, and characterization of elusive or time-sensitive targets. By significantly reducing the cost and complexity of traditional spaceborne radar architectures, Kapta is enabling a new class of scalable, mission-driven sensing capabilities for defense and intelligence customers. For more information on Kapta Space, go to our website at www.kaptaspace.com.

Media Contact
[email protected] 

About Washington Harbour Partners
Washington Harbour Partners, based in Washington DC, is a private investment firm that brings a fresh approach to investors and founders, providing flexibility and deep operational expertise at all stages of the investment cycle – from growth equity to control buyouts. The firm has deep domain expertise in the areas of national security, defense technologies, cybersecurity, enterprise technologies, and technology-enabled services. In 2026, Washington Harbour Partners ranked sixth among all defense technology investors, and the highest ranked non-government affiliated firm to also fund private equity investments, in the Silicon Valley Defense Group’s NatSec100 report, investing in 16 of the companies named to the list. For more information, please visit https://washingtonharbour.com/

Media Contact
[email protected]

SOURCE Kapta Space

Eclipse leads financing as Oxide reaches profitability and AMD Ventures invests in its systems-based approach to enterprise computing

EMERYVILLE, Calif., Oct. 9, 2026 — Oxide Computer Company, the on-premises cloud computing company, today announced it has raised a $445 million Series D led by Eclipse, with participation from existing investors US Innovative Technology Fund (USIT), Riot Ventures, Jane Street, and more. New investors Atreides Management and AMD Ventures also joined the round.

Oxide entered rarefied air earlier this year as it reached profitability, a significant milestone for a rapidly scaling hardware company. With customer demand exceeding current production capacity, the Series D provides additional working capital to secure components, increase manufacturing and serve new and existing customers.

“The accelerating pace of on-prem cloud computing projects has required us to scale manufacturing capacity by 20x over the past 12 months, and yet demand still exceeds supply,” said Steve Tuck, co-founder and CEO at Oxide. “We’re well-capitalized, and hit an important profitability milestone earlier this year. This funding will allow us to aggressively invest in the materials and manufacturing scale our customers need for years to come.”

Oxide’s growth comes as the rise of agentic AI intensifies demand for infrastructure that can support a growing mix of compute, memory, networking and data-intensive workloads. The level of complexity required to support these agentic workloads is only achievable or scalable with full-stack systems – something that historically only the world’s largest cloud providers could offer and at a price point that is cost-prohibitive for many organizations. With demand for compute, memory and data center capacity outpacing supply, even the hyperscalers are struggling to keep up. These dynamics reinforce that enterprises need the ability to own and control the systems their most critical workloads run on in order to ensure on-demand access to reliable, secure and cost-effective computing.

The Oxide Cloud Computer is a rack-scale integrated system with purpose-built hardware and open-source software that brings the architectural model of the hyperscale cloud to an organization’s own data center. By co-designing compute, storage, networking, and software as a single system, Oxide gives enterprises cloud automation and agility with direct ownership over their security, performance, data, and economics.

“The next infrastructure bottleneck is already taking shape. As AI shifts from generating answers to executing work, demand for CPU-based systems is accelerating dramatically,” said Seth Winterroth, Eclipse partner. “Oxide was built for this moment. Steve, Bryan, and the team saw years ago that enterprises would need cloud-scale computing they could own and control, and they built the full system to deliver it. Now they’re scaling to meet a market that is moving faster than anyone anticipated.”

“When we started Oxide in 2019, we knew that there would be increasing demand for owning and operating one’s own compute — and we felt strongly that organizations should be able to control their infrastructure without having to forfeit the modernity of cloud computing,” said Bryan Cantrill, CTO and co-founder of Oxide.  “The specifics have been surprising — we certainly did not anticipate the explosion in compute demand from agentic AI — but today’s thirst to control one’s own fate is exactly what we sought to slake with Oxide.”

Oxide made an early bet that the next era of computing would be built as systems with hardware and software designed together rather than assembled from disparate components. AMD and Oxide have worked closely across the hardware and software stack. As agentic AI creates new demands across compute, memory and networking, AMD Ventures is deepening that relationship through a strategic investment in Oxide.

“Oxide’s systems-level approach to enterprise infrastructure is expanding the choices available to customers as their computing needs become more complex,” said Sagi Paz, Head of AMD Ventures. “This approach aligns with AMD’s commitment to fostering a broad, high-performance computing ecosystem, and we’re excited to support the company’s next phase of growth.”

Oxide customers span organizations with demanding infrastructure requirements across financial services, government, national laboratories, aerospace, and other compute-intensive industries. This infusion of capital further strengthens Oxide’s ability to invest for the long term as customers deploy its infrastructure for increasingly critical workloads.

To learn more, visit oxide.computer.

About Oxide
Oxide Computer Company is the creator of the Cloud Computer, a rack-scale system with fully unified hardware and open-source software purpose-built to deliver hyperscale cloud computing to on-premises data centers. Oxide gives developers the elasticity, programmability and unified control of the cloud while enabling enterprises to retain ownership of their infrastructure for greater security, latency, sovereignty and cost predictability. Founded in 2019, Oxide is based in Emeryville, California.

Media Contact
[email protected] 

SOURCE Oxide

New capital will accelerate product development and enterprise growth as demand rises for the company’s “Storm Tracker for the Internet.”

MINNEAPOLIS, Oct. 9, 2026 — GUDEA, the AI-powered narrative intelligence platform known as the “Storm Tracker for the Internet,” today announced the close of an oversubscribed $7 million seed-stage financing co-led by Mudita Ventures and Collide Capital. The new capital will fund accelerated product development, expanded platform coverage, and enterprise growth as organizations increasingly turn to narrative intelligence to understand the forces shaping online conversation.

Online narratives now move from a single post to a market-moving story in a matter of hours, and a growing body of research shows that much of that conversation is not what it appears to be. GUDEA’s own analyses have repeatedly found that small groups of users exhibiting inauthentic behavior drive an outsized share of online discussion on topics ranging from consumer brands to financial markets. Most organizations have no way to see those dynamics, leaving communicators, strategists, and investor relations teams to respond to narratives without knowing where they came from, who is driving them, or where they are headed.

GUDEA closes that gap. The platform combines behavioral intelligence, graph neural network modeling, and real-time monitoring across dozens of online platforms to show clients where narratives originate, which users are driving them, and how quickly they are likely to spread. It distinguishes authentic engagement from inauthentic behavior and classifies audiences into five distinct categories, giving organizations an early, evidence-based view of emerging risk. GUDEA’s data has informed reporting by national news outlets, its platform supports Fortune 100 companies and leading communications firms, and the company was named a 2026 SXSW Pitch finalist and a 2026 Webby Award nominee.

“Every organization now operates inside an information environment it does not control and often cannot see,” said Keith Presley, co-founder and CEO of GUDEA. “Narratives shape markets, brands, and public trust long before they show up in a headline. The demand behind this round reflects a simple reality: leaders need to know what is moving online, who is moving it, and what happens next. We are scaling the platform and the team to give them exactly that.”

Buddy Foster, an investor at Mudita Ventures, added, “The information environment has become a core business risk, and GUDEA measures it with a rigor we have not seen anywhere else in the market. Keith and his team pair deep intelligence experience with technology that already delivers for demanding clients, and we are proud to back them as they scale.”

Founded in 2023 by Keith Presley, Jonathan Sperber, and James Thomin, whose backgrounds span military intelligence, national security operations, and artificial intelligence, GUDEA has seen rapidly growing demand from enterprises, public institutions, and security-sensitive organizations. The seed capital will support continued investment in the platform’s predictive modeling capabilities, expansion of the engineering and go-to-market teams, and broader coverage across platforms, languages, and regions.

For more information, visit gudea.ai.

About GUDEA
GUDEA is an AI-powered narrative intelligence platform that helps organizations understand how narratives form and spread across the digital landscape. By combining natural language analysis with behavioral modeling, GUDEA empowers leaders to anticipate public perception, identify key influencers, and respond to emerging conversations before they define reality.

SOURCE GUDEA

Points essentiels

• Si l’on ajoute à cela son tour de table « Seed » de 8,5 millions de dollars, l’entreprise a levé plus de 16,5 millions de dollars pour financer ses activités.
• Vinci Pharmaceuticals a clôturé un tour de table de série A de plus de 8 millions de dollars destiné à financer les activités de fabrication, de contrôle qualité et de mise sur le marché, ainsi que les premiers essais cliniques chez l’homme de sa plateforme d’administration de médicaments EPIPLANT™.
• EPIPLANT™, la plateforme exclusive de l’entreprise dédiée à l’administration épisclérale de médicaments à libération prolongée, est conçue pour pallier les limites des injections intraoculaires.
• Une étude clinique de phase 1/2a est prévue pour 2027.

AVON-BY-THE-SEA, New Jersey, 9 octobre 2026 — Vinci Pharmaceuticals Inc., une société pharmaceutique spécialisée dans les produits ophtalmiques, a clôturé un tour de table de série A de plus de 8 millions de dollars alors que la société poursuit le développement de sa plateforme innovante de diffusion EPIPLANT™. Auparavant, l’entreprise avait levé 8,5 millions de dollars, hors intérêts sur les obligations convertibles, dans le cadre d’un financement de démarrage, pour un total de plus de 16,5 millions de dollars.

Développé dans le laboratoire du Dr Karl Csaky, MD, PhD, et sous licence de la Retina Foundation of the Southwest à Dallas, au Texas, EPIPLANT™ est une plateforme exclusive d’implants épiscléraux conçue pour assurer une libération prolongée de médicaments dans les tissus rétiniens et pallier les limites associées aux injections intraoculaires. Vinci poursuit ce programme avec le soutien de son comité consultatif scientifique composé de médecins.

Ce tour de table a été mené par Dynagrow Capital, LLLP, avec le soutien de MintPharma Capital. Les fonds levés dans le cadre de ce financement devraient servir à financer les activités de fabrication en environnement GMP, de contrôle et de mise sur le marché du produit EPIPLANT™ VCI-002, ainsi que l’étude de phase 1/2a prévue en 2027.

« Nous sommes reconnaissants du soutien et de la confiance que nous témoignent nos investisseurs et notre conseil d’administration, qui reconnaissent le potentiel de notre système d’administration EPIPLANT™ pour transformer le traitement des maladies menaçant la vue et répondre aux besoins non satisfaits dans ce domaine », a déclaré Philip A. Gioia, cofondateur, président-directeur général de Vinci Pharmaceuticals. « Ce financement permet de franchir une nouvelle étape importante : nous nous préparons à mener notre première étude chez l’homme. Nous pensons qu’EPIPLANT™ a le potentiel d’assurer une administration sûre et prolongée de médicaments aux tissus rétiniens et d’alléger la charge thérapeutique pour les patients et les médecins. »

Sarah Hassan, directrice générale de Dynagrow Capital, a ajouté : « Le projet EPIPLANT de Vinci pourrait marquer un véritable tournant pour les ophtalmologues et leurs patients confrontés aux défis posés par les maladies rétiniennes. Cette technologie potentielle de plateforme multimoléculaire, qui repose sur un système d’administration sans aiguille destiné aux petites molécules, pourrait considérablement améliorer l’observance thérapeutique chez les patients qui présentent actuellement un taux d’abandon inacceptable en raison de la charge que représente le traitement. « Nous sommes ravis de nous associer à la talentueuse équipe de Vinci et de la soutenir en cette période cruciale pour la mise à disposition de l’EPIPLANT VCI-002 aux patients. »

La société a obtenu plusieurs brevets portant sur sa technologie exclusive EPIPLANT™ et a mené à bien des essais précliniques préliminaires. Vinci prévoit de lancer en 2027 une étude clinique de phase 1/2a, la première à être menée chez l’homme.

Les méthodes actuelles d’administration de médicaments pour traiter les maladies rétiniennes nécessitent souvent une injection directe dans l’œil ou se heurtent à des difficultés pour atteindre des concentrations thérapeutiques efficaces dans les tissus rétiniens. EPIPLANT™ est conçu pour pallier ces limites grâce à une libération prolongée du médicament à partir d’un implant épiscléral. Cette plateforme bioérodable est conçue pour accueillir toute une gamme de principes actifs pharmaceutiques et pourrait ainsi servir de support à plusieurs traitements destinés aux maladies de la rétine.

« EPIPLANT™ permet d’acheminer des concentrations ciblées de médicament vers la macula, ce qui en fait une option plus intéressante pour le traitement de certaines maladies ophtalmiques de la rétine que les injections intravitréennes, qui constituent actuellement la norme de soins, » a déclaré le Dr Richard Lindstrom, de Minnesota Eye Consultants. « La technologie EPIPLANT™ ouvre également la voie à de nouvelles thérapies pour des pathologies rétiniennes qui ne bénéficient actuellement d’aucun traitement. »

Vinci Pharmaceuticals prévoit de mener un essai clinique de phase 1/2a sur son système d’administration épiscléral à libération prolongée EPIPLANT™ en 2027 À l’heure actuelle, le système permet d’administrer des petites molécules, ce qui ouvre la voie à de nombreuses applications pour diverses maladies de la rétine.

À propos de Vinci Pharmaceuticals
Vinci Pharmaceuticals Inc. est une société ophtalmologique prête à entrer en phase clinique qui s’appuie sur une plateforme innovante et exclusive pour développer des produits « premiers de leur catégorie », « les meilleurs de leur catégorie » et « uniques en leur genre », dotés de profils différenciés, destinés au traitement de certaines maladies de la rétine.

Clause de non-responsabilité
Le présent communiqué de presse contient des déclarations prospectives, qui comprennent des informations relatives à des événements futurs, aux performances financières futures, aux prévisions financières, aux stratégies, aux attentes, à l’environnement concurrentiel et à la réglementation.  Les déclarations prospectives ne doivent pas être interprétées comme une garantie de performances ou de résultats futurs et peuvent ne pas constituer des indications précises quant au moment où ces performances ou résultats seront atteints.Les déclarations prospectives reposent sur les informations dont dispose Vinci Pharmaceuticals au moment où elles sont formulées ou sur les convictions de bonne foi de la direction à cette date concernant des événements futurs ; elles sont soumises à des risques et incertitudes susceptibles d’entraîner un écart significatif entre les performances ou résultats réels et ceux exprimés ou suggérés dans ces déclarations prospectives.

Contact
Vinci Pharmaceuticals Inc.
Phil Gioia
Cofondateur, président-directeur général
E-mail : [email protected]

Middle school launches in summer 2027 and high school in summer 2028. Core instructional materials will be free to every teacher, school, district, and family, and teachable with no screens at all or with technology used carefully.

WASHINGTON, Oct. 9, 2026 — Modern Classrooms Project, a nonprofit focused on improving math instruction, announced a $12 million funding round, led by the Skeebo Foundation, to build a complete Tier 1 math curriculum grounded in cognitive science and free to anyone who wants to use it. The curriculum will launch in summer 2027 with middle school. High school will launch in summer 2028.

For more than a decade, American students have lost ground in math, and the students who were already behind have lost the most. Scores peaked in 2013 and have fallen since. On the 2024 Nation’s Report Card, 72 percent of eighth graders scored below proficient in math, and the gap between the highest- and lowest-performing students was the widest in the history of the assessment.

Modern Classrooms Project’s math curriculum will draw on decades of cognitive science research on how students learn math. “Many in the learning science community have been passionate that their research is not being applied to math classrooms at scale,” said Kareem Farah, CEO and Co-Founder of Modern Classrooms Project and a former high school math teacher. “Until a math curriculum is released that anchors on cognitive science and is free to anyone who wants it, we cannot fully test whether that body of research is the missing piece to improve math outcomes at scale.”

Every class period in the curriculum will have a clear research-informed design: whole-group fluency, then one new skill taught explicitly and accompanied by guided practice and blocked practice, a short skill check, then spaced practice in which skills taught weeks earlier come back interleaved. Because math is hierarchical, every skill is checked the day it is taught, and skills return multiple times throughout the year until they are mastered.

The base version of the curriculum will be completely paper-based and designed for traditional implementation: an educator facilitates whole-group fluency, explicit instruction and guided practice from the front of the room, with blocked practice, skill checks and assessments completed on paper.

A second implementation pathway will be designed for teachers, schools, and systems seeking to leverage technology thoughtfully to more effectively cater to learners’ needs. In this pathway, students will be able to access elements of instruction digitally and will progress through the content at a flexible pace based on mastery. This will allow educators to spend the bulk of class time in one-on-one and small-group instruction, using data to address misunderstandings precisely.

Modern Classrooms Project is committed to working with teachers, schools, and districts where they are in their instructional journey, supporting both implementation pathways and studying how each impacts teacher efficacy and student achievement.

The core instructional materials in the curriculum, both student-facing and teacher-facing, will be free and publicly available: ready to print, free to modify, and aligned to standards.

In the coming weeks, Modern Classrooms Project will be announcing its research advisory board, a committed group of cognitive scientists, mathematicians, and education researchers who will help guide key product decisions.

Modern Classrooms Project is looking to grow its community of collaborators as it builds the curriculum: teachers interested in testing early prototypes, schools and districts interested in piloting the curriculum, and research partners interested in studying the curriculum’s impacts.

Learn more and get involved at modernclassrooms.org/curriculum.

About Modern Classrooms Project

Modern Classrooms Project is a nonprofit organization that empowers educators to transform their classrooms and schools to meet the needs of every student. Our educator-led, mastery-based instructional approach, grounded in the science of learning, is the foundation of a growing movement of tens of thousands of educators worldwide. Together with our curriculum- and standards-aligned tools, content, and resources, we are reshaping how teaching and learning happen across the country. Learn more at modernclassrooms.org.

SOURCE Modern Classrooms Project

CARACAS, Venezuela, Oct. 9, 2026 — Representatives of the Belén Clarisa Velutini Trust, established by the founder of Trasnocho Cultural, announced an estimated US$40 million real estate investment over the next 36 months aimed at comprehensively modernizing one of Venezuela’s most promising independent cultural centers, MP Publishing reported.

“The planned investment began with a comprehensive renovation of the operational infrastructure and technological upgrades to the cinema and theater facilities,” announced Jorge Kiriakidis of KLMC Legal, representing the Herrera Velutini family trust, which owns the complex.

The announcement comes as Venezuela enters a new phase of recovery, infrastructure modernization and renewed interest from domestic and international investors.

Trasnocho Cultural is an urban hub comprising the cultural center, the Paseo Las Mercedes hotel and Trasnocho Mall—a mixed-use model that integrates culture, entertainment, dining, retail and hospitality. Over its 25 years of operation, the concept has attracted the attention of international cultural managers and industry professionals interested in replicating a model of this kind. In Miami, a city where the cultural sector has been steadily expanding, discussions have also taken place about the possibility of developing initiatives inspired by the Caracas concept.

The next phase will be an ambitious renovation project for the Paseo Las Mercedes hotel, part of the complex, which is expected to become one of the most modern and luxurious hotels in southeastern Caracas. According to Kiriakidis, the new design preserves the original architectural lines of the project by renowned Venezuelan architect Jimmy Alcock, which is considered part of the country’s cultural heritage because of its architectural and urban significance.

The investment comes at a time of transformation for Venezuela. After years of infrastructure deterioration and limited investment, the country has begun to attract renewed capital and private-sector projects, while multilateral institutions are exploring new avenues for participation in its recovery. The Inter-American Development Bank has begun developing a two-year work plan, with an initial focus on the country’s electricity infrastructure and social protection needs.

“Since its creation, the Herrera Velutini family has been committed to keeping the Trasnocho cultural model operational, a formula that remains relatively uncommon in the region. The challenge now is not only to improve the spaces and preserve the legacy, but also to expand the offering with programming that is attractive to younger generations and creates a more welcoming and modern experience for all audiences,” Kiriakidis added.

According to the attorney, the initiative represents much more than a physical renovation. It is an investment in improving quality of life, revitalizing Venezuela’s cultural and entertainment offerings, and honoring the legacy of international entrepreneur, banker and investor Belén Clarisa Velutini, one of Venezuela’s leading private patrons of culture and a descendant of a historic family closely associated with the country’s financial development.

“She also carried out numerous social initiatives that we are now expanding through a foundation bearing her name,” said Melanie de Herrera Velutini, the foundation’s president. “The idea is to continue that part of her legacy through projects focused on children’s education and development, civic education, and, of course, humanitarian support and cultural development initiatives.”

SOURCE MP Publishing

CARACAS, Venezuela, 9 de octubre de 2026 /PRNewswire-HISPANIC PR WIRE/ — Representantes del trust Belén Clarisa Velutini, fundadora del complejo Trasnocho Cultural, anunciaron una inversión inmobiliaria de aproximadamente 40 millones de dólares en los próximos 36 meses, destinada a la modernización integral de uno de los centros culturales independientes de más proyección en Venezuela, informó MP Publishing.

“La inversión planificada comenzó con la renovación integral de la infraestructura operativa y la actualización tecnológica en las salas de cine y teatro”, anunció Jorge Kiriakidis, de KLMC legal, representante del fideicomiso de la familia Herrera Velutini, propietaria del complejo.

El anuncio se produce en momentos cuando Venezuela inicia una nueva etapa de recuperación, modernización de infraestructura y renovado interés de inversionistas nacionales e internacionales.

Trasnocho Cultural es un hub urbano conformado por el centro cultural, el hotel Paseo Las Mercedes y el Trasnocho Mall, un modelo de uso mixto que integra cultura, entretenimiento, gastronomía, comercio y hospitalidad. A lo largo de sus 25 años de operaciones, el concepto ha llamado la atención de gestores y personas vinculadas al sector cultural internacional, interesados en replicar un modelo de estas características. Incluso en Miami, una ciudad donde la oferta cultural ha venido ganando espacio, se han adelantado conversaciones acerca de la posibilidad de desarrollar propuestas inspiradas en el concepto caraqueño.

Lo siguiente será el desarrollo de un ambicioso proyecto de renovación para el hotel Paseo Las Mercedes, parte del complejo, y que se convertirá en uno de los más modernos y lujosos del sureste de Caracas. Según Kiriakidis, el nuevo diseño se hizo preservando las líneas originales de la obra del reconocido arquitecto venezolano Jimmy Alcock, considerada patrimonio cultural por su valor arquitectónico y urbano.

La inversión se produce en un momento de transformación para Venezuela. Tras años de deterioro en su infraestructura y una limitada inversión, el país ha comenzado a atraer nuevamente capital y proyectos privados, mientras organismos multilaterales evalúan nuevas vías de participación en su recuperación. El Banco Interamericano de Desarrollo ha comenzado a elaborar un plan de trabajo de dos años, con especial atención inicial a las necesidades de infraestructura eléctrica y protección social.

“Desde su creación, la familia Herrera Velutini se ha empeñado en mantener operativo  el modelo cultural de Trasnocho, que sigue siendo una fórmula poco habitual en la región. El reto ahora no solo es mejorar los espacios y mantener el legado, sino ampliar la propuesta con una agenda atractiva para las nuevas generaciones, más amable y moderna para todo el público”, agregó Kiriakidis.

Según el abogado, la iniciativa representa mucho más que una renovación física: es una apuesta por mejorar la calidad de vida, revitalizar la oferta cultural de entretenimiento de los venezolanos y al mismo tiempo, honrar el legado de la empresaria, banquera e inversionista internacional Belén Clarisa Velutini, una de las principales promotoras privadas de la cultura en Venezuela, descendiente de una histórica familia vinculada al desarrollo financiero del país.

«Ella también hizo muchas obras sociales que hoy estamos ampliando a través de una Fundación que lleva su nombre—, informó su presidenta, Melanie de Herrera Velutini—, y la idea es continuar esa parte de su legado en proyectos de formación educativa infantil, educación cívica y por supuesto, iniciativas de apoyo humanitario y desarrollo cultural.”

FUENTE MP Publishing

PHOENIX, Oct. 8, 2026 — Trinity Capital Inc. (NYSE: TRIN) (the “Company”), a leading alternative asset manager, today announced a portfolio update for the third quarter and first three quarters of 2026. Trinity Capital originated $880 million of new commitments in the third quarter of 2026, bringing new commitments for the first three quarters of 2026 to $2.0 billion.

Third quarter 2026 investment highlights:

• Gross investments funded totaled approximately $614 million, which was comprised of $378 million in secured loans, $159 million in equipment financings and $77 million in warrant and equity investments.
• The Company originated approximately $880 million of new commitments, which was comprised of $534 million in secured loans, $270 million in equipment financings and $76 million in equity investments.
• The Company funded approximately $432 million to 15 new portfolio companies, $118 million to 24 existing portfolio companies and $64 million to multi-sector holdings.
• Gross proceeds received from repayments and exits of the Company’s investments totaled approximately $495 million, which included $237 million from debt investments sold, $195 million from early debt repayments and refinancings, $57 million from scheduled/amortizing debt payments and $6 million from warrant and equity exits.

Aggregate investment highlights for the first three quarters of 2026:

• Gross investments funded totaled approximately $1.5 billion, which was comprised of $1.1 billion in secured loans, $322 million in equipment financings and $131 million in warrant and equity investments.
• The Company originated approximately $2.0 billion of total new commitments, which was comprised of $1.5 billion in secured loans, $380 million in equipment financings and $131 million in equity investments.
• The Company funded approximately $927 million to 36 new portfolio companies and $526 million to 35 existing portfolio companies and $86 million to multi-sector holdings.
• Gross proceeds received from repayments and exits of the Company’s investments totaled approximately $1.1 billion, which included $523 million from early debt repayments and refinancings, $381 million from debt investments sold, $184 million from scheduled/amortizing debt payments and $22 million from warrant and equity exits.

Trinity Capital will release its complete third quarter 2026 financial results on Wednesday, November 4, 2026 and will discuss its financial results on a conference call the same day at 12:00 p.m. ET.

To listen to the call, please dial (800) 267-6316 or (203) 518-9783 internationally and reference Conference ID: TRINQ326 if asked, approximately 10 minutes prior to the start of the call. A live webcast of the third quarter 2026 financial results conference call will also be available on the Investor Relations section of the Company’s website at ir.trinitycapital.com. A replay will be available on the Company’s website for 90 days following the conference call.

About Trinity Capital Inc.

Trinity Capital Inc. (NYSE: TRIN) is an international alternative asset manager that seeks to deliver consistent returns for investors through access to private credit markets. Trinity Capital sources and structures investments in well-capitalized growth-oriented companies across five distinct lending verticals: Sponsor Finance, Equipment Finance, Tech Lending, Asset Based Lending, and Healthcare & Life Sciences. Headquartered in Phoenix, Arizona, Trinity Capital’s dedicated team is strategically located across the United States and Europe. For more information on Trinity Capital, please visit trinitycapital.com and stay connected to the latest activity via LinkedIn.

Forward-Looking Statements

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements other than statements of historical facts included in this press release may constitute forward-looking statements and are not guarantees of future performance or results and involve a number of risks and uncertainties. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described from time to time in filings with the Securities and Exchange Commission (“SEC”). The Company undertakes no duty to update any forward-looking statement made herein, except as required by law. All forward-looking statements speak only as of the date of this press release. More information on risks and other potential factors that could affect the Company’s financial results, including important factors that could cause actual results to differ materially from plans, estimates or expectations, is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed annual report on Form 10-K and subsequent SEC filings.

SOURCE Trinity Capital Inc.

Wichtigste Erkenntnisse

• Zusammen mit der Seed-Finanzierungsrunde in Höhe von 8,5 Mio. US-Dollar hat das Unternehmen mehr als 16,5 Mio. US-Dollar zur Unterstützung seiner Aktivitäten eingeworben.
• Vinci Pharmaceuticals hat eine Serie-A-Finanzierungsrunde in Höhe von über 8 Mio. US-Dollar abgeschlossen, um die Herstellung, Test- und Freigabeverfahren sowie die ersten Studien am Menschen für seine Arzneimittelverabreichungsplattform EPIPLANT™ zu unterstützen.
• EPIPLANT™, die firmeneigene, episklerale Wirkstofffreisetzungsplattform mit verzögerter Freisetzung, wurde entwickelt, um die Einschränkungen intraokularer Injektionen zu überwinden.
• Eine klinische Phase-1/2a-Studie ist für 2027 geplant.

AVON-BY-THE-SEA, New Jersey, 8. Oktober 2026 — Vinci Pharmaceuticals Inc., ein auf Augenheilkunde spezialisiertes Pharmaunternehmen, hat eine Serie-A-Finanzierungsrunde in Höhe von über 8 Mio. US-Dollar abgeschlossen, während das Unternehmen die Entwicklung seiner innovativen EPIPLANT™-Verabreichungsplattform vorantreibt. Zuvor hatte das Unternehmen in der Seed-Phase 8,5 Mio. US-Dollar (ohne Zinsen auf Wandelanleihen) eingeworben, was einer Gesamtsumme von mehr als 16,5 Mio. US-Dollar entspricht.

EPIPLANT™ wurde im Labor von Dr. med. Karl Csaky, PhD, entwickelt und von der Retina Foundation of the Southwest in Dallas, Texas, lizenziert. Es handelt sich um eine firmeneigene episklerale Implantatplattform, die eine verzögerte Wirkstoffabgabe an das Netzhautgewebe ermöglicht und die mit intraokularen Injektionen verbundenen Einschränkungen überwindet. Vinci treibt das Programm unter Anleitung seines wissenschaftlichen Beirats aus Ärzten voran.

Die Finanzierung wurde von Dynagrow Capital, LLLP geleitet, mit Unterstützung von MintPharma Capital. Die Erlöse aus der Finanzierung sollen die GMP-konforme Herstellung, die Test- und Freigabeaktivitäten für das Produkt EPIPLANT™ VCI-002 sowie 2027 die Phase-1/2a-Studie unterstützen.

„Wir sind dankbar für die Unterstützung und das Vertrauen unserer Investoren und unseres Vorstands, die erkennen, dass unser EPIPLANT™-Verabreichungssystem erkennen, die Behandlung von sehkraftbedrohenden Erkrankungen zu revolutionieren und bisher ungedeckte Bedürfnisse in diesem Bereich zu erfüllen”, sagte Philip A. Gioia, Mitbegründer, Vorstandsvorsitzender und Geschäftsführer von Vinci Pharmaceuticals. „Diese Finanzierung unterstützt einen wichtigen nächsten Schritt: die Vorbereitung unserer ersten Studie am Menschen. Wir glauben, dass EPIPLANT™ das Potenzial hat, eine sichere, nachhaltige Wirkstoffabgabe an das Netzhautgewebe zu gewährleisten und die Behandlungsbelastung für Patienten und Ärzte zu verringern.”

Sarah Hassan, Geschäftsführerin bei Dynagrow Capital, fügte hinzu: „Vincis EPIPLANT stellt einen potenziellen Paradigmenwechsel für Augenärzte und ihre Patienten dar, die mit den Herausforderungen von Netzhauterkrankungen konfrontiert sind. Diese potenzielle Multi-Molekül-Plattformtechnologie mit einem nadelfreien Verabreichungssystem für kleine Moleküle könnte die Therapietreue von Patienten drastisch verbessern, bei denen derzeit aufgrund der Behandlungsbelastung eine inakzeptabel hohe Abbruchrate zu verzeichnen ist. Wir freuen uns, mit dem talentierten Team von Vinci zusammenzuarbeiten und es in dieser entscheidenden Phase bei der Weiterentwicklung von EPIPLANT VCI-002 für Patienten zu unterstützen.”

Dem Unternehmen wurden mehrere Patente für seine firmeneigene EPIPLANT™-Technologie erteilt, und es hat vorläufige präklinische Tests abgeschlossen. Vinci plant, 2027 eine erste klinische Phase-1/2a-Studie am Menschen zu starten.

Bestehende Ansätze zur Wirkstoffabgabe bei Netzhauterkrankungen erfordern häufig eine Verabreichung direkt ins Auge oder stehen vor der Herausforderung, wirksame Wirkstoffkonzentrationen im Netzhautgewebe zu erreichen. EPIPLANT™ wurde entwickelt, um diese Einschränkungen durch eine nachhaltige Wirkstoffabgabe aus einem episkleralen Implantat zu überwinden. Die bioerodierbare Plattform ist für eine Vielzahl von pharmazeutischen Wirkstoffen ausgelegt und bietet das Potenzial, verschiedene Therapien für Netzhauterkrankungen zu unterstützen.

„EPIPLANT™ sorgt für gezielte Wirkstoffkonzentrationen in der Makula und ist damit im Vergleich zu intravitrealen Injektionen, dem derzeitigen Behandlungsstandard, eine wünschenswertere Option zur Behandlung bestimmter augenheilkundlicher Erkrankungen der Netzhaut”, sagte Dr. med. Richard Lindstrom von Minnesota Eye Consultants. „Die EPIPLANT™-Technologie eröffnet zudem neue Therapiemöglichkeiten für Netzhauterkrankungen, für die es derzeit noch keine Behandlung gibt.”

Vinci Pharmaceuticals plant für 2027 eine klinische Phase-1/2a-Studie mit seinem episkleralen EPIPLANT™-System zur verzögerten Wirkstofffreisetzung. Derzeit kann das System kleine Moleküle abgeben, was eine breite Anwendung bei verschiedenen Netzhauterkrankungen ermöglicht.

Informationen zu Vinci Pharmaceuticals
Vinci Pharmaceuticals Inc. ist ein klinisch ausgereiftes Unternehmen im Bereich der Augenheilkunde, das eine neuartige, firmeneigene Plattform nutzt, um „First-in-Class”, „Best-in-Class” und „Only-in-Class”-Produkte mit differenzierten Profilen zur Behandlung bestimmter Erkrankungen der Netzhaut zu entwickeln.

Safe-Harbor
Diese Pressemitteilung enthält zukunftsgerichtete Aussagen, darunter Informationen zu zukünftigen Ereignissen, der zukünftigen finanziellen Entwicklung, Finanzprognosen, Strategien, Erwartungen, dem Wettbewerbsumfeld und regulatorischen Rahmenbedingungen. Zukunftsgerichtete Aussagen sind nicht als Garantie für zukünftige Leistungen oder Ergebnisse zu verstehen und stellen möglicherweise keine genauen Hinweise darauf dar, wann solche Leistungen oder Ergebnisse erzielt werden. Zukunftsgerichtete Aussagen basieren auf Informationen, über die Vinci Pharmaceuticals zum Zeitpunkt der Äußerung dieser Aussagen verfügt, oder auf der zu diesem Zeitpunkt bestehenden, nach bestem Wissen und Gewissen getroffenen Einschätzung der Unternehmensleitung hinsichtlich zukünftiger Ereignisse und unterliegen Risiken und Ungewissheiten, die dazu führen könnten, dass die tatsächlichen Leistungen oder Ergebnisse wesentlich von den in den zukunftsgerichteten Aussagen zum Ausdruck gebrachten oder angedeuteten abweichen.

Kontakt:
Vinci Pharmaceuticals Inc.
Phil Gioia
Mitbegründer, Vorstandsvorsitzender und CEO
E-Mail: [email protected]